Antibodies
The present invention relates to an anti-CSF-1R antibody and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The present invention also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment.
1. An anti-colony stimulating factor 1 receptor (CSF-1R) antibody comprising:
i) a heavy chain, wherein the variable domain of the heavy chain comprises SEQ ID NO:4 for CDR-H1, SEQ ID NO:5 for CDR-H2 and SEQ ID NO:6 for CDR-H3; and
ii) a light chain, wherein the variable domain of the light chain comprises SEQ ID NO:1 for CDR-L1, SEQ ID NO:2 for CDR-L2 and SEQ ID NO:3 for CDR-L3.
2. The anti-CSF-1R antibody according to claim 1 , wherein the heavy chain comprises SEQ ID NO:23.
3. The anti-CSF-1R antibody according to claim 1 , wherein the light chain comprises SEQ ID NO:15.
4. The anti-CSF-1R antibody according to claim 1 , wherein the antibody molecule is selected from the group consisting of: a complete antibody molecule having full length heavy and light chains or an antigen binding fragment thereof.
5. The anti-CSF-1R antibody according to claim 1 , said antibody having an effector or a reporter molecule attached to it.
6. The anti-CSF-1R antibody according to claim 1 , having a binding affinity for human CSF-1R of 10 pM or less.
7. An isolated DNA sequence encoding the heavy and/or light chain(s) of an antibody according to claim 1 .
8. A cloning or expression vector comprising one or more DNA sequences according to claim 7 .
9. The vector according to claim 8 , wherein the vector comprises SEQ ID NO:28 and/or SEQ ID NO:20.
10. A host cell comprising one or more cloning or expression vectors according to claim 9 .
11. A process for the production of an antibody, comprising culturing the host cell of claim 10 and isolating the antibody.
12. A pharmaceutical composition comprising an antibody according to claim 1 , in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier, wherein the pharmaceutical composition optionally comprises other active ingredients.
13. An anti-colony stimulating factor 1 receptor (CSF-1R) antibody, having a heavy chain comprising SEQ ID NO:23 and a light chain comprising SEQ ID NO: 15, or having a heavy chain comprising SEQ ID NO:27 and a light chain comprising SEQ ID NO:19.